Identification of sex-determining region Y (SRY) in maternal plasma after paternal lymphocyte immunization: is it possible?

Am J Reprod Immunol. 2012 Mar;67(3):231-4. doi: 10.1111/j.1600-0897.2011.01082.x. Epub 2011 Oct 27.

Abstract

Problem: Women treated with allogeneic immunization using paternal lymphocytes often request laboratory molecular tests using cell-free fetal DNA in maternal plasma. There is concern whether the treatment can interfere with its results. This study evaluated the applicability of fetal sex determination using fragments of sex-determining region Y (SRY) in the plasma of women submitted to paternal lymphocyte immunization.

Method of study: Non-pregnant women blood samples were collected at two different moments: prior to paternal lymphocyte immunization and after three doses of the immunotherapy, in a prospective study. For women who became pregnant, another sample was collect during the first trimester. Amplification of the fragment of the Y chromosome (SRY) was performed using real-time PCR.

Results: The SRY gene was not identified in any of the plasma samples of the 50 non-pregnant women submitted to paternal lymphocyte immunization at either of the two moments evaluated. For the 26 pregnant women, the results of the identification of sex -determining in maternal plasma were completely in agreement with the infant sex.

Conclusion: Paternal lymphocyte immunization does not affect the results of SRY fragment investigation in the plasma of women submitted to paternal lymphocyte immunization therapy.

MeSH terms

  • Abortion, Habitual / immunology*
  • Abortion, Habitual / therapy*
  • Female
  • Fetus
  • Humans
  • Immunotherapy
  • Lymphocytes / immunology*
  • Male
  • Pregnancy
  • Prenatal Diagnosis
  • Sex Determination Analysis*
  • Sex-Determining Region Y Protein / blood*

Substances

  • SRY protein, human
  • Sex-Determining Region Y Protein